Osteoporosis prevention and therapy: preserving and building strength through bone quality (Q36565785)

15 August 2017

1 reference

title

Osteoporosis prevention and therapy: preserving and building strength through bone quality (English)

1 reference

15 August 2017

Kleerekoper M

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

15 August 2006

1 reference

Osteoporosis International

15 August 2017

published in

1 reference

15 August 2017

volume

17

1 reference

15 August 2017

issue

12

1 reference

15 August 2017

page(s)

1707-1715

1 reference

Estrogen and bone metabolism

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00198-006-0187-X

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-006-0187-X

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-006-0187-X

Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-006-0187-X

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

21 January 2018

1 reference

12 December 2020

Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women

1 reference

12 December 2020

Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography.

1 reference

12 December 2020

Is bone mineral density predictive of fracture risk reduction?

1 reference

12 December 2020

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

1 reference

12 December 2020

Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women

1 reference

12 December 2020

Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women

1 reference

12 December 2020

Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis 1

1 reference

12 December 2020

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

1 reference

12 December 2020

Calcitonin prevents bone loss but decreases osteoblastic activity in ovariohysterectomized beagle dogs

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Effect of hormone replacement therapy on bone quality in early postmenopausal women

1 reference

12 December 2020

Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial

1 reference

12 December 2020

A new treatment for post-menopausal osteoporosis: strontium ranelate.

1 reference

12 December 2020

Two biochemical indices of mouse bone formation are increased, in vivo, in response to calcitonin

1 reference

12 December 2020

Effects of calcitonin on animal and in vitro models of skeletal metabolism

1 reference

12 December 2020

Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women

1 reference

12 December 2020

Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group

1 reference

12 December 2020

A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates

1 reference

12 December 2020

Osteonecrosis of the jaw and bisphosphonates

1 reference

12 December 2020

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

1 reference

12 December 2020

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin

1 reference

12 December 2020

Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy

1 reference

12 December 2020

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

1 reference

12 December 2020

Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography

1 reference

12 December 2020

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

12 December 2020

The structural and biomechanical basis of the gain and loss of bone strength in women and men.

1 reference

12 December 2020

Long-term calcitonin therapy in postmenopausal osteoporosis

1 reference

12 December 2020

Mechanisms underlying the effects of phosphate and calcitonin on bone histology in postmenopausal osteoporosis

1 reference

12 December 2020

Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials

1 reference

12 December 2020

Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography

1 reference

12 December 2020

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

1 reference

12 December 2020

Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer

1 reference

12 December 2020

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Bazedoxifene (Wyeth).

1 reference

12 December 2020

Raloxifene effects on vasomotor and other climacteric symptoms in postmenopausal women

1 reference

12 December 2020

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

1 reference

12 December 2020

Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration

1 reference

12 December 2020

Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats

1 reference

12 December 2020

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

1 reference

12 December 2020

Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats

1 reference

12 December 2020

Sex steroids and bone

1 reference

12 December 2020

Severely suppressed bone turnover: a potential complication of alendronate therapy

1 reference

12 December 2020

Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis

1 reference

12 December 2020

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

1 reference

12 December 2020

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

12 December 2020

Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women

1 reference

12 December 2020

The role of calcitonin in the prevention of osteoporosis.

1 reference

12 December 2020

Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal women

1 reference

12 December 2020

The effects of hormone replacement therapy on cortical bone in postmenopausal women. A histomorphometric study.

1 reference

12 December 2020

Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women

1 reference

12 December 2020

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

12 December 2020

Calcitonin for osteoporosis and bone pain

1 reference

12 December 2020

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

1 reference

12 December 2020

Low Frequency of Treatment of Osteoporosis Among Postmenopausal Women Following a Fracture

1 reference

12 December 2020

Trabecular bone microarchitecture after alendronate treatment of osteoporotic women

1 reference

12 December 2020

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

1 reference

12 December 2020

Effects of a one-year administration of phosphate and intermittent calcitonin on bone-forming and bone-resorbing cells in involutional osteoporosis: a histomorphometric study

1 reference

12 December 2020

Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study

1 reference

12 December 2020

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

1 reference

12 December 2020

10.1007/S00198-006-0187-X

Identifiers

DOI

1 reference

15 August 2017

1 reference